Piramal Pharma Ltd
Piramal Pharma Q2 Results 2026 (FY27): Revenue ₹2,617 Cr, PAT ₹5 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #37 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Piramal Pharma Ltd Q2 FY27 key numbers
- Revenue
- Q2FY27 revenue from operations: ₹2,617 Crores, up 28% YoY from ₹2,044 Crores in Q2FY26 (Page 21, Page 4).
As stated in Piramal Pharma Ltd's Q2 FY27 investor presentation · published 27 Oct 2026. Reported figures, not investment advice.
Based on Piramal Pharma Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2FY27 revenue from operations: ₹2,617 Crores, up 28% YoY from ₹2,044 Crores in Q2FY26 (Page 21, Page 4). EBITDA for Q2FY27: ₹385 Cr., up 72% YoY from ₹224 Cr.
From Piramal Pharma Ltd's Q2 FY27 earnings-call transcript · updated 27 Oct 2026.
Revenue & Sales Performance
- Q2FY27 revenue from operations: ₹2,617 Crores, up 28% YoY from ₹2,044 Crores in Q2FY26 (Page 21, Page 4).
- Segment-wise Q2FY27 revenue and YoY growth:
- CDMO: ₹1,424 Cr, +36% YoY
- CHG: ₹849 Cr, +32% YoY
- PCH: ₹359 Cr, +13% YoY (Page 21).
- H1FY27 revenue from operations: ₹4,887 Crores, up 23% YoY from ₹3,977 Crores in H1FY26 (Page 21).
- FY27 outlook: upgraded revenue growth guidance to 19-20% for the full year, with meaningfully higher profitability expected (Page 9, Page 2).
2 more points from Piramal Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Piramal Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Lexington expansion: On track to strengthen sterile fill-finish capabilities—this is the final step of the integrated ADC platform. A new microbiology laboratory at the site has been commissioned. (Page 12)
- Continued investments in capacities and capabilities across the CDMO network with focus on biologics platform strengthened through acquisition of controlling stake in Yapan Bio. (Page 12)
- Intangible Assets Under Development (IAUD) related to capex stood at ₹1,271 Cr as of 30-Sep-26, up from ₹1,100 Cr in March 2026, reflecting ongoing asset creation. (Page 22)
- (Pages 12 and 22)
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Piramal Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Piramal Pharma Ltd's call on order book
Create a free account to keep reading this call
Piramal Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.6K Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Piramal Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Piramal Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Piramal Pharma Ltd Q2 FY27 results?
Q2FY27 revenue from operations: ₹2,617 Crores, up 28% YoY from ₹2,044 Crores in Q2FY26 (Page 21, Page 4). EBITDA for Q2FY27: ₹385 Cr., up 72% YoY from ₹224 Cr.
What is Piramal Pharma Ltd share price analysis?
Piramal Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹26,457 Cr. Investors should review the full earnings analysis for detailed insights.
Is Piramal Pharma Ltd planning capital expenditure?
Lexington expansion: On track to strengthen sterile fill-finish capabilities—this is the final step of the integrated ADC platform.
Keep Piramal Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.